List view / Grid view
Researchers at Tokyo University of Science have identified three new enzyme families that degrade the complex bacterial carbohydrate β-1,2-glucan – offering new opportunities for enzyme engineering.
Lab scientists and data scientists often speak different languages and that miscommunication can slow down important research. In this interview, Ian Kerman shares how his team is working to break down those walls and spark better collaboration.
EPFL scientists have engineered virus-inspired DNA aptamers that bind infection targets with record selectivity. This innovation could change how we diagnose and treat infectious diseases.
Nearly a billion people are affected by chronic organ scarring, yet treatments remain limited. Now, Duke-NUS researchers have compiled a scientific ‘handbook’ of immune cell insights that could fast-track breakthroughs in fibrosis therapy.
A new study suggests statins, cheap and widely used cholesterol drugs, could be repurposed to reduce the risk of death from sepsis. Researchers reported a 39 percent drop in 28-day mortality, highlighting their potential role in critical care.
5 June 2025 | By WuXi Biologics
Stop costly biologic failures. This masterclass reveals high-throughput strategies to optimize antibody leads upfront.
Despite the promise of gene therapies, automated red blood cell exchange (aRBCX) remains an underutilised therapy in the management of sickle cell disease (SCD). In this article, Dr Aaron Haubner and Carly Newton of Terumo Blood and Cell Technologies, highlight the urgent need for partnerships and equitable access to this…
Chief Scientific Officer at Solvias reveals how CROs are overcoming manufacturing challenges and harnessing AI to fast-track the development of groundbreaking cell and gene therapies.
Three-dimensional (3D) models are reshaping pre-clinical drug development by providing more accurate insights into drug safety and efficacy. Explore how these advanced in vitro systems help improve predictions and reduce the risk of failure in early-stage drug discovery.
In this first interview of a two-part series, Andreas Kolleger explores the convergence of knowledge graphs and large language models. As the head of GenAI innovation at Neo4j, Andreas brings a unique cross-industry perspective on how these technologies can enhance life sciences workflows.
Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.
The FORESIGHT consortium has secured €9 million to speed up drug development using advanced molecular imaging, targeting major diseases like cancer, autoimmune conditions, and heart disorders.
Scientists identify thousands of novel enhancers linked to neuronal differentiation and neuropsychiatric disorders, offering new pathways for drug discovery and potential therapeutic targets.
Macrocycles outperform traditional therapeutics on several fronts, yet they account for just four percent of FDA-approved drugs. Colleagues Ann E Cleves and Ajay N Jain from Optibrium Ltd explain why we can expect to see this number increase in the coming years.
In part two of the step-by-step scientific workflow for drug discovery series, Dr Raminderpal Singh and Nina Truter describe the functions of the workflow previously outlined and include key considerations.
